NCT05773105View on ClinicalTrials.gov

A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2025

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

Cadonilimab+regorafenib

cadonilimab(10mg/kg, iv,Q3W,D1) + regorafenib(80mg,PO,QD,everyday)

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER